Newnew
2021-07-06
Good 👍
U.S. FDA declines to approve Provention Bio's diabetes drug
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":157182587,"tweetId":"157182587","gmtCreate":1625572937049,"gmtModify":1633939534787,"author":{"id":3583016139705080,"idStr":"3583016139705080","authorId":3583016139705080,"authorIdStr":"3583016139705080","name":"Newnew","avatar":"https://static.tigerbbs.com/c1f72fa81dd8aa4df22904e9ff7b7c9b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good 👍 </p></body></html>","htmlText":"<html><head></head><body><p>Good 👍 </p></body></html>","text":"Good 👍","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/157182587","repostId":1164032536,"repostType":4,"repost":{"id":"1164032536","kind":"news","pubTimestamp":1625570893,"share":"https://www.laohu8.com/m/news/1164032536?lang=&edition=full","pubTime":"2021-07-06 19:28","market":"us","language":"en","title":"U.S. FDA declines to approve Provention Bio's diabetes drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1164032536","media":"Reuters","summary":"(Reuters) -The U.S. Food and Drug Administration on Tuesday declined to approve Provention Bio Inc’s","content":"<p>(Reuters) -The U.S. Food and Drug Administration on Tuesday declined to approve Provention Bio Inc’s experimental diabetes drug teplizumab, citing insufficient data, the company said on Tuesday.</p>\n<p>The health regulator said a study in healthy volunteers to compare planned commercial product with the drug product used in the company’s clinical trials had failed to show comparability.</p>\n<p>The agency asked the company to establish comparability between the two products or provide other data that adequately justifies why it would not be necessary, Provention Bio said.</p>\n<p>It also cited deficiencies related to a recent inspection at a manufacturing plant used by the company.</p>\n<p>The company expects to collect the additional comparability data from a sub-study of the drug, intended for the delay of clinical type 1 diabetes, later this quarter.</p>\n<p>Trading in shares of Provention Bio were halted.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. FDA declines to approve Provention Bio's diabetes drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. FDA declines to approve Provention Bio's diabetes drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 19:28 GMT+8 <a href=https://www.reuters.com/article/provention-fda/update-1-u-s-fda-declines-to-approve-provention-bios-diabetes-drug-idUSL3N2OI2NC><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -The U.S. Food and Drug Administration on Tuesday declined to approve Provention Bio Inc’s experimental diabetes drug teplizumab, citing insufficient data, the company said on Tuesday.\nThe ...</p>\n\n<a href=\"https://www.reuters.com/article/provention-fda/update-1-u-s-fda-declines-to-approve-provention-bios-diabetes-drug-idUSL3N2OI2NC\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRVB":"Provention Bio, Inc"},"source_url":"https://www.reuters.com/article/provention-fda/update-1-u-s-fda-declines-to-approve-provention-bios-diabetes-drug-idUSL3N2OI2NC","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164032536","content_text":"(Reuters) -The U.S. Food and Drug Administration on Tuesday declined to approve Provention Bio Inc’s experimental diabetes drug teplizumab, citing insufficient data, the company said on Tuesday.\nThe health regulator said a study in healthy volunteers to compare planned commercial product with the drug product used in the company’s clinical trials had failed to show comparability.\nThe agency asked the company to establish comparability between the two products or provide other data that adequately justifies why it would not be necessary, Provention Bio said.\nIt also cited deficiencies related to a recent inspection at a manufacturing plant used by the company.\nThe company expects to collect the additional comparability data from a sub-study of the drug, intended for the delay of clinical type 1 diabetes, later this quarter.\nTrading in shares of Provention Bio were halted.","news_type":1},"isVote":1,"tweetType":1,"viewCount":355,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/157182587"}
精彩评论